Jim Simons Uro Gen Pharma Ltd. Transaction History

Renaissance Technologies LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$10.87 - $15.93 $750,030 - $1.1 Million	-69,000 Reduced 43.04%	91,300 $1.37 Million
Q3 2023 Nov 14, 2023	BUY	$8.84 - $22.64 $762,892 - $1.95 Million	86,300 Added 116.62%	160,300 $2.25 Million
Q2 2023 Aug 11, 2023	BUY	$8.75 - $14.29 $227,500 - $371,540	26,000 Added 54.17%	74,000 $766,000
Q1 2023 May 12, 2023	BUY	$7.99 - $11.02 $37,553 - $51,794	4,700 Added 10.85%	48,000 $444,000
Q4 2022 Feb 13, 2023	BUY	$7.55 - $11.9 $1,510 - $2,380	200 Added 0.46%	43,300 $384,000

Q3 2022 Nov 14, 2022	SELL	$7.21 - $9.41 $3,605 - $4,705	-500 Reduced 1.15%	43,100 $359,000
Q2 2022 Aug 12, 2022	BUY	$5.12 - $8.74 $96,768 - $165,186	18,900 Added 76.52%	43,600 $357,000
Q1 2022 May 13, 2022	BUY	$5.92 - $9.73 $146,224 - $240,331	24,700 New	24,700 $215,000
Q1 2021 May 13, 2021	SELL	$17.99 - $26.96 $590,072 - $884,288	-32,800 Closed	0 $0
Q4 2020 Feb 10, 2021	BUY	$17.54 - $25.43 $575,312 - $834,104	32,800 New	32,800 $591,000
Q2 2019 Aug 12, 2019	SELL	$32.75 - $40.35 $262,000 - $322,800	-8,000 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$35.47 - $54.55 $283,760 - $436,400	8,000 New	8,000 $296,000

113

24M

46.9K

44.3K

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $361M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.